HER2 negative metastatic breast cancer
Clinical trials for HER2 negative metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HER2 negative metastatic breast cancer trials appear
Sign up with your email to follow new studies for HER2 negative metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new chemo schedule extend life with fewer side effects?
Disease control CompletedThis trial tests three different schedules of the chemotherapy drug nab-paclitaxel (Abraxane) in women with HER2-negative metastatic breast cancer. The goal is to find a schedule that allows patients to stay on treatment longer, potentially improving progression-free survival, wh…
Matched conditions: HER2 NEGATIVE METASTATIC BREAST CANCER
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Head-to-Head: which chemo works better for HER2-Negative breast cancer?
Disease control CompletedThis trial compares two chemotherapy drugs—cabazitaxel given every three weeks versus paclitaxel given weekly—as a first treatment for HER2-negative metastatic breast cancer. About 90 to 160 participants receive 18 weeks of one of the two drugs. The main goal is to see which drug…
Matched conditions: HER2 NEGATIVE METASTATIC BREAST CANCER
Phase 2 • Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC